NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

Matinas BioPharma Holdings, Inc. (MTNB) Stock Analysis

Matinas BioPharma Holdings, Inc. (MTNB) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

MTNB

$0.18

+$0.00 (+0.55%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MTNB with… →

MTNB Key Statistics

As of Sep 4, 2026
Trading
Open
$0.18
Previous Close
$0.18
Day's Range
0.17–0.19
52-Week Range
0.17–2.14
Volume
1.17M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.70
Valuation
Market Cap
$2.67M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.16
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$10.35M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
14.69M
1-Year Return
−89.23%
Dividend and dates
Avg Volume
5.58M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MTNB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−68.94%
2025+14.90%
2024−95.28%
2023−56.80%
2022−50.50%
2021−25.74%
2020−40.09%
2019+281.51%
2018−48.71%
2017−17.14%
2016 (partial year)+115.38%

As of September 4, 2026.

MTNB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$10.35M—
2024$0.00−$24.25M—
2023$1.10M−$22.94M−2093.2%
2022$3.19M−$21.00M−658.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$6.96M−$10.35M—
2024$0.00—−$20.16M−$24.25M—
2023$1.10M—−$23.77M−$22.94M−2093.2%
2022$3.19M—−$24.59M−$21.00M−658.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MTNB Valuation vs Biotechnology Median

Median of 656 stocks
MetricMTNBBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Matinas BioPharma Holdings, Inc. (MTNB) carries a market capitalisation of $2.67M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 2.

The 52-week range on file runs from $0.17 to $2.14. The most recent close on file for MTNB is $0.18, dated September 4, 2026. That is $0.00 (+0.55%) against the previous close. The latest close sits 5.2% above that 52-week low.

Financial Health

In fiscal 2025, Matinas BioPharma Holdings, Inc. reported revenue of $0.00. The same year closed with a net loss of $10.35M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.16.

Across the 4 fiscal years on file, revenue moves from $3.19M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is −89.23%. Across 10 years the annualized return works out at −41.80%. Beta against the wider market is reported at 1.7. Daily returns over the trailing 10 years annualize to a volatility of 146.23%.

Growth & Income

The record shows no dividend for MTNB.

So far in 2026 the price is −68.94%. The strongest complete calendar year on file is 2019 at +281.51%; the weakest is 2024 at −95.28%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Matinas BioPharma Holdings, Inc. (MTNB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Matinas BioPharma Holdings, Inc. MTNB $2.67M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Matinas BioPharma Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Visit website →